Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification
NCT ID: NCT04765150
Last Updated: 2025-05-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
275 participants
OBSERVATIONAL
2021-04-01
2027-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Artificial Intelligence-Based Computer-Aided Diagnosis of Prostate Cancer
NCT05513638
AI Algorithm-Informed Biopsy for Prostate Cancer Detection With Indeterminate and Low-Risk Prostate MRI Lesions
NCT07231627
Investigation of Impact of AI on Prostate Cancer Workflow
NCT07084779
Comprehensive Evaluation of MRI-AI in Prostate Cancer Diagnosis
NCT06575361
Validation of a Machine Learning Model Based on MR for the Prediction of Prostate Cancer
NCT06773598
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To develop and evaluate quantitative dynamic contrast-enhanced (DCE)-MRI analysis techniques that minimize patient- and scanner-specific variabilities in the calculation of quantitative parameters.
II. To develop and evaluate diffusion weighted imaging (DWI) methods that reduce prostate geometric distortion due to patient- and scanner-specific susceptibility and eddy current effects.
III. To develop and evaluate multi-class deep learning models that systematically integrate quantitative multi-parametric (mp)-MRI features for accurate detection and classification of clinically significant prostate cancer (csPCa).
OUTLINE:
RETROSPECTIVE: Patients' medical records are reviewed.
PROSPECTIVE: Patients undergo additional 3 Tesla (T) MRI imaging over 30 minutes before, during, or after their standard of care 3T MRI for a total of 1.5 hours.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Observational (electronic health record review, 3 T MRI)
RETROSPECTIVE: Patients' medical records are reviewed.
PROSPECTIVE: Patients undergo additional 3T MRI imaging over 30 minutes before, during, or after their standard of care 3T MRI for a total of 1.5 hours.
3 Tesla Magnetic Resonance Imaging
Undergo 3T MRI
Electronic Health Record Review
Medical charts are reviewed
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
3 Tesla Magnetic Resonance Imaging
Undergo 3T MRI
Electronic Health Record Review
Medical charts are reviewed
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical suspicion of prostate cancer or biopsy-confirmed prostate cancer
* Undergone or undergoing multi-parametric 3 T prostate MRI at the University of California at Los Angeles (UCLA)
* Ability to provide consent
Exclusion Criteria
* Contraindications to gadolinium contrast-based agents other than the possibility of an allergic reaction to the gadolinium contrast-based agent
* Prior radiotherapy
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
National Cancer Institute (NCI)
NIH
Jonsson Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kyung H Sung, PhD
Role: PRINCIPAL_INVESTIGATOR
UCLA / Jonsson Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2021-00373
Identifier Type: REGISTRY
Identifier Source: secondary_id
19-002202
Identifier Type: OTHER
Identifier Source: secondary_id
441480-KS-29447
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
19-002202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.